



PATIENT

Zuki Pinto

SPECIES

Canine

BREED

Maltese

SEX

Female Spayed

AGE

13 years

WEIGHT

13.1lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Diane McFadden

HOSPITAL NAME

Basking Ridge Animal
Hospital

REFERRING VET

Dr. Blachek

INVOICE

26551

DATE

9/26/22

PRESENTING CLINICAL SIGNS

History: Previous echo from 2/22/22 showed moderate MR and LA dilation. Grade 4/6 murmur. elevated liver enzymes.

-Abnormal PE/Chem/CBC/UA Results: ALT 559, AST 136, ALKP 844, GGT 28.

-Current medications: pimobendan 1.25mg x 1.5 tabs bid; Lasix 12.5mg x 1 in am and 1/2 in pm.

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. The mitral valve is diffusely thickened with prolapse into the left atrial lumen. There is severe eccentric mitral regurgitation present. The MR velocity is normal. There is severe left atrial enlargement. There is mild left ventricular dilation. Left ventricular systolic function is hyperdynamic. Normal right heart. Mild thickening of the tricuspid valve with septal prolapse and mild to moderate TR. Normal velocity. There is normal systolic flow velocity across the aortic valve. The aortic valve appears trileaflet with normal mobility. The main pulmonary artery is normal in diameter. The pulmonic valve is normal in appearance. No pericardial/pleural effusion or cardiac masses are seen.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.8	2.4	2.0	2.0	54	86	0.2
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg: 2D and m-mode short axis (cm)	LVIDs Avg: 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	188	1.0		5.9	2.3	3.1	1.4
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease causing severe mitral and mild to moderate tricuspid regurgitation. The LA is significantly dilated indicating a high risk for clinical signs going forward. No additional concurrent issues such as systolic dysfunction are documented. Without the prior report, progression is speculative; however, severe disease is identified here.

Given these findings, reasonable to continue Pimobendan going forward, with addition of Spironolactone and an ACE-I due to severity of disease. Lasix has been prescribed without



PATIENT

Zuki Pinto

reported clinical signs or history of CHF. This should only be continued if either of these are documented. Assessment of progression in the future will help predict long term outcome, however prognosis is guarded at this stage (late B2). Unfortunately, the patient will always be at risk for recurrent CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future.

SPECIES

Canine

Close monitoring for development of associated clinical signs (development of a cough, labored breathing, exercise intolerance or worsening collapse episodes) is recommended. Monitoring of sleeping breathing rates is recommended as the best way to screen for CHF at home.

BREED

Maltese

Elective anesthesia is not advised, as there is high risk for complication. If necessary, cardiac protective drug choices (opioid/benzodiazepine premedication, propofol or alfaxalone induction, iso or sevoflurane gas) are recommended. Pre-oxygenate for 5-10 minutes prior to induction and recover in O2 cage. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Moderate IV fluid restriction is recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

SEX

Female Spayed

AGE

13 years

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit.

WEIGHT

13.1lbs

PLAN

A screening BP is recommended. Continue Pimobendan 0.3mg/kg PO q12h. Institute ACE-I (benazepril or enalapril) 0.5mg/kg PO q12h. Institute spironolactone 1-2mg/kg PO q12h. If is or has been documented, continue Lasix otherwise this can be discontinued.

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

Monitor renal values in 1-2 weeks, then every 3-4 months lifelong to ensure tolerance of medications.

IMAGING PERFORMED BY


Diane McFadden

A recheck echocardiogram is recommended in 4-6 months to screen for progression, sooner if clinical signs arise.

HOSPITAL NAME

Basking Ridge Animal
Hospital

IMAGES



REFERRING VET

Dr. Blachek

INVOICE

26551

DATE

9/26/22



PATIENT

Zuki Pinto

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

SPECIES

Canine

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

BREED

Maltese

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com

SEX

Female Spayed

AGE

13 years

WEIGHT

13.1lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

**IMAGING
PERFORMED BY**

Diane McFadden

HOSPITAL NAME

Basking Ridge Animal
Hospital

REFERRING VET

Dr. Blachek

INVOICE

26551

DATE

9/26/22